GSK plc GSK
LSE · United Kingdom · Health Technology
GBp 1,810.50-21.50 (-1.17%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Fresh funding from the Gates Foundation for AN2 Therapeutics’ tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group’s boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the very short term, with a 1-day share price return of a 0.22% decline and a 7-day share price return of a 2.62% decline, even as fresh R&D headlines such as the Gates backed TB work and recent conference appearances keep the pipeline in view. Yet momentum...
– Hatteras holds first closing of Hatteras Opportunity Fund II (HOF II) – – HOF II closing brings capital under management to over $1 billion – DURHAM, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Hatteras Venture Partners, a venture capital firm focused on transformative healthcare innovation, has appointed two longtime healthcare leaders to senior roles as it builds its next generation of companies and expands support for later-stage portfolio businesses. Sir Andrew Witty, former Chief Executive O
GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.